Asset Details
Do you wish to reserve the book?
Long-term results of two unconventional agents in steroid-dependent nephrotic children
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-term results of two unconventional agents in steroid-dependent nephrotic children
Do you wish to request the book?
Long-term results of two unconventional agents in steroid-dependent nephrotic children
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-term results of two unconventional agents in steroid-dependent nephrotic children
2005
Overview
Children with steroid-dependent minimal change nephrotic syndrome are prone to serious steroid side effects. Alternative therapies, such as oral cyclophosphamide, may also have serious side effects. We conducted this novel prospective study to compare the long-term efficacies of levamisole and I.V. pulse cyclophosphamide as therapies with potentially fewer side effects. This study included 40 children with idiopathic steroid-dependent minimal change nephrotic syndrome (age 3-15 years; 31 boys and 9 girls). The patients were randomized into two equal groups. One group received levamisole 2.5 mg/kg on alternate days (levamisole group) while the other group received I.V. cyclophosphamide 500 mg/m2/month for six months (cyclophosphamide group). Prednisolone was gradually withdrawn. After stopping treatment, the number of patients that maintained remission was five (25%) in each group at six months, four (20%) versus two (10%) at one year and three (15%) versus one (5%) at two years in the levamisole and cyclophosphamide groups respectively, and one (5%) in each group at three and four years. The overall side effects were mild and both drugs were well tolerated. In view of the results, we recommend trial of levamisole before adopting other therapies with more serious side effects in such patients.
Publisher
Springer,Springer Nature B.V
Subject
/ Child
/ Children
/ Complications and side effects
/ Cyclophosphamide - adverse effects
/ Cyclophosphamide - therapeutic use
/ Drug Administration Schedule
/ Female
/ Glucocorticoids - administration & dosage
/ Glucocorticoids - adverse effects
/ Glucocorticoids - therapeutic use
/ Humans
/ Levamisole - adverse effects
/ Levamisole - therapeutic use
/ Male
/ Nephrosis, Lipoid - drug therapy
/ Nephrotic Syndrome - drug therapy
/ Patients
/ Prednisolone - administration & dosage
/ Prednisolone - adverse effects
/ Prednisolone - therapeutic use
/ Proteins
/ Steroids
/ Urine
